A Randomized Controlled Trial to Compare the Efficacy and Safety of Lumateperone Versus Olanzapine-Fluoxetine Combination in the Treatment of Bipolar Depression

Study OverviewThis research protocol outlines a 12-week, randomized, open-label, parallel-group clinical trial to compare the efficacy and safety of Lumateperone against the standard Olanzapine-Fluoxetine Combination (OFC) for treating bipolar depression.

Background & RationaleWhile OFC is a proven, FDA-approved treatment for bipolar depression, it is heavily associated with adverse metabolic side effects, such as weight gain and metabolic syndrome. This is especially concerning in South Asian populations who are at a higher baseline risk for these issues. Lumateperone is a newer, FDA-approved atypical antipsychotic that shows similar promise for treating depressive symptoms but with a much safer metabolic profile. Currently, there are no head-to-head trials comparing the two, particularly in an Indian demographic.

Key Methodological Details****Study Setting & Population: 30 adult patients (ages 18–65) with Bipolar I or II Disorder currently in a major depressive episode, recruited from AIIMS Bathinda.Intervention Arms: Arm A: Lumateperone (42 mg/day).Arm B: OFC (Olanzapine 5 mg + Fluoxetine 20 mg/day).Primary Endpoint: The mean change in depressive symptom severity from baseline to the end of the 12-week phase, measured by the Montgomery–Asberg Depression Rating Scale (MADRS).Secondary Endpoints: Response rates ($ge$ 50% MADRS reduction), remission rates (MADRS $le$ 10), and overall improvements in clinical status and quality of life (measured via CGI-S, CGI-I, and Q-LES-Q-SF).Analysis: Data will be analyzed using Intention-to-Treat (ITT) and Per-Protocol approaches in SPSS, assessing both symptom reduction and metabolic tolerability.